You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 14, 2025

Details for Patent: 12,083,227


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 12,083,227
Title:Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis
Abstract:The present disclosure relates to pharmaceutical compositions comprising a gonadotropin-releasing hormone (GnRH) antagonist and methods of preparing and using such compositions. The disclosure also relates to methods of facilitating release of a GnRH antagonist from a pharmaceutical composition.
Inventor(s):Yihong Qiu, Yuchuan Gong, Alexander RUGGLES, Jared A. Baird, Hui Zu, Gregory A. McClelland, Anna V. Stepanenko
Assignee:Neurocrine Biosciences Inc, AbbVie Inc
Application Number:US16/105,440
Patent Claim Types:
see list of patent claims
Patent landscape, scope, and claims:

Understanding the Scope and Claims of United States Patent 12,083,227: A Detailed Analysis

Introduction

When analyzing a patent, particularly one like United States Patent 12,083,227, it is crucial to delve into the scope and claims to understand its implications and validity. This article will provide a comprehensive analysis of the patent landscape, focusing on the key aspects of patent claims, subject matter eligibility, and the recent updates from the USPTO.

Patent Claims and Scope

Patent claims are the heart of any patent application, defining the scope of the invention and what is protected by the patent. The length and clarity of these claims are critical factors in determining patent quality and scope[3].

Independent Claim Length and Count

Research has shown that the length and count of independent claims can be simple yet effective metrics for measuring patent scope. Patents with narrower claims, both in terms of length and count, tend to have a higher probability of grant and a shorter examination process. This is because narrower claims are often clearer and more specific, reducing the likelihood of disputes over their meaning[3].

Subject Matter Eligibility

Subject matter eligibility is a pivotal aspect of patent law, particularly in the context of recent updates from the USPTO.

2024 USPTO Guidance Update

The 2024 USPTO guidance update clarifies several key points regarding subject matter eligibility, especially for AI-assisted inventions. The update emphasizes that the method of invention development, including the use of AI, does not impact subject matter eligibility. Instead, the focus remains on the claimed invention itself, ensuring that AI-assisted inventions are evaluated on equal footing with other technologies[1].

Practical Applications and Judicial Exceptions

To be patent-eligible, claims must integrate judicial exceptions (such as abstract ideas or natural phenomena) into practical applications. This integration is crucial for transforming the claim into patent-eligible subject matter.

Example from the 2024 Guidance Update

For instance, consider a claim involving the separation of audio signals and the application of mathematical algorithms to enhance clarity. If the claim merely involves receiving, separating, and processing audio signals without any practical application, it would be considered ineligible as it does not add any inventive concept or practical application to the abstract idea. However, if the claim specifies the use of the separated audio components in a real-time speech recognition system to enhance the accuracy of voice commands in hands-free environments, it would be considered patent-eligible. This additional step provides a practical application that results in tangible benefits, such as improved noise reduction and enhanced accuracy in speech recognition systems[1].

Incorporation of Recent Case Law

Recent case law has further refined the understanding of subject matter eligibility. For example, the case of Hyatt v. PTO highlights the importance of timely disclosure of claims and the consequences of withholding claims to separate inventions. This case underscores the need for applicants to ensure that all relevant claims are disclosed in a timely manner to avoid restriction requirements and potential delays in the patent examination process[2].

Determining Inventorship

Inventorship is another critical aspect of patent law. US patent law stipulates that whoever invents the patentable subject matter is entitled to a patent. Errors in inventorship can have significant consequences, including the invalidation of the patent if there is deceptive intent involved[5].

Patent Examination Process

The patent examination process plays a crucial role in shaping the scope of patent claims. The examination process tends to narrow the scope of patent claims, both in terms of claim length and count, especially when the duration of examination is longer. This narrowing helps in ensuring that the granted patents have clear and specific claims, reducing the risk of litigation and licensing disputes[3].

Real-World Applications and Benefits

Highlighting the real-world applications and benefits of the claimed method or system is essential for bolstering the argument for patent eligibility. Demonstrating how the abstract idea is applied in a way that provides concrete benefits or solves specific problems in the relevant field is crucial. For example, in the case of the audio signal separation claim, specifying the use in a real-time speech recognition system enhances the accuracy of voice commands, providing tangible benefits such as improved noise reduction and enhanced functionality in voice-controlled systems[1].

Key Takeaways

  • Subject Matter Eligibility: Claims must integrate judicial exceptions into practical applications to be patent-eligible.
  • AI-Assisted Inventions: The use of AI in invention development does not impact subject matter eligibility; the focus remains on the claimed invention itself.
  • Practical Applications: Specifying the use of the claimed method or system in a real-world application is crucial for demonstrating patent eligibility.
  • Inventorship: Accurate disclosure of inventors is essential; errors can lead to patent invalidation.
  • Patent Examination: The examination process narrows the scope of patent claims, ensuring clarity and specificity.

Frequently Asked Questions (FAQs)

Q: How does the 2024 USPTO guidance update impact AI-assisted inventions? A: The update clarifies that the method of invention development, including the use of AI, does not impact subject matter eligibility. AI-assisted inventions are evaluated on equal footing with other technologies, provided there is significant human contribution[1].

Q: What is the importance of practical applications in patent claims? A: Practical applications are essential for transforming abstract ideas into patent-eligible subject matter. They provide concrete benefits or solve specific problems in the relevant field, making the claim patent-eligible[1].

Q: How does the patent examination process affect the scope of patent claims? A: The examination process tends to narrow the scope of patent claims, both in terms of length and count, especially when the duration of examination is longer. This ensures that the granted patents have clear and specific claims[3].

Q: What are the consequences of errors in inventorship? A: Errors in inventorship can lead to patent invalidation if there is deceptive intent involved. Even if the correct inventorship can be established, a patent obtained through fraud remains unenforceable[5].

Q: How can the scope of patent claims be measured? A: The scope of patent claims can be measured using metrics such as independent claim length and independent claim count. Narrower claims are associated with a higher probability of grant and a shorter examination process[3].

Cited Sources

  1. Understanding the 2024 USPTO Guidance Update on AI Patent - Mintz.
  2. HYATT v. PTO - United States Court of Appeals for the Federal Circuit.
  3. Patent Claims and Patent Scope - Hoover Institution.
  4. Search for patents - USPTO - USPTO.
  5. Determining Inventorship for US Patent Applications - Oregon State University.

More… ↓

⤷  Try for Free


Drugs Protected by US Patent 12,083,227

Showing 1 to 1 of 1 entries

International Family Members for US Patent 12,083,227

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Australia 2018317472 ⤷  Try for Free
Australia 2018317473 ⤷  Try for Free
Australia 2018419533 ⤷  Try for Free
Brazil 112020003380 ⤷  Try for Free
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 4 of 4 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.